会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • PREDICTIVE MODELS AND METHODS FOR DIAGNOSING AND ASSESSING CORONARY ARTERY DISEASE
    • 预测模型和方法诊断和评估冠状动脉疾病
    • WO2009049257A9
    • 2009-10-29
    • PCT/US2008079646
    • 2008-10-10
    • CARDIO DX INCROSENBERG STEVEDANIELS SUSANELASHOFF MICHAEL RWINGROVE JAMES ATINGLEY WHITTEMORE GSEHNEERT AMY JPAONI NICHOLAS F
    • ROSENBERG STEVEDANIELS SUSANELASHOFF MICHAEL RWINGROVE JAMES ATINGLEY WHITTEMORE GSEHNEERT AMY JPAONI NICHOLAS F
    • C12Q1/68
    • C12Q1/6883C12Q2600/112C12Q2600/158
    • Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCFl (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIGl, 0LIG2, AD0RA3, CLC, and SLC29A1 (group II); and CBS and ARGl (group IV).
    • 提供用于诊断和评估冠状动脉疾病(CAD)程度的生物标志物,以及用于测量其表达的试剂盒。 本发明还提供了基于生物标志物的预测模型以及计算机系统和用于对样品进行评分和任选分类的模型的软件实施例。 在一个优选的实施方案中,生物标志物被组织成群集。 组内生物标志物的表达水平在正常和疾病状态下彼此高度相关。 可以使用从2,3,4或5个群集基因组A,B,C,D,E中的每一个中选择的基因的表达值。 或者,将选自这些基因的基因的表达值组合成一种变应原。 优选的生物标志物包括S100A12,S100A8,S100A9,BCL2A1和F5(A组); XK,P62和FECH(B组); TUBB2(C组); IFNG,PDGFB,VSIG4和TNF(D组); CSF3R,TLR5,CD46和NCF1(E组); S100A12,S100A9,BCL2A1,TXN和CSTA(组I); OLIG1,0LIG2,AD0RA3,CLC和SLC29A1(组II); 和CBS和ARG1(第IV组)。
    • 6. 发明申请
    • PREDICTIVE MODELS AND METHODS FOR DIAGNOSING AND ASSESSING CORONARY ARTERY DISEASE
    • 用于诊断和评估冠状动脉疾病的预测模型和方法
    • WO2009049257A3
    • 2009-07-02
    • PCT/US2008079646
    • 2008-10-10
    • CARDIO DX INCROSENBERG STEVEDANIELS SUSANELASHOFF MICHAEL RWINGROVE JAMES ATINGLEY WHITTEMORE GSEHNEERT AMY JPAONI NICHOLAS F
    • ROSENBERG STEVEDANIELS SUSANELASHOFF MICHAEL RWINGROVE JAMES ATINGLEY WHITTEMORE GSEHNEERT AMY JPAONI NICHOLAS F
    • C12Q1/68
    • C12Q1/6883C12Q2600/112C12Q2600/158
    • Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCFl (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIGl, 0LIG2, AD0RA3, CLC, and SLC29A1 (group II); and CBS and ARGl (group IV).
    • 提供了有助于诊断和评估冠状动脉疾病(CAD)程度的生物标志物,以及用于测量其表达的试剂盒。 本发明还提供了基于生物标志物的预测模型,以及用于评分和可选地分类样品的模型的计算机系统和软件实施方案。 在优选的实施方案中,生物标志物被组织成聚集的组。 一组中生物标志物的表达水平在正常和疾病状态下彼此高度相关。 可以使用从两个,三个,四个或五个聚簇基因组A,B,C,D,E中的每一个中选择的基因的表达值。 或者,选自组中的基因的表达值被组合成元源。 优选的生物标志物包括S100A12,S100A8,S100A9,BCL2A1和F5(组A); XK,P62和FECH(B组); TUBB2(C组); IFNG,PDGFB,VSIG4和TNF(D组); CSF3R,TLR5,CD46和NCF1(组E); S100A12,S100A9,BCL2A1,TXN和CSTA(组I); OLIG1,0LIG2,AD0RA3,CLC和SLC29A1(组II); 和CBS和ARG1(组IV)。